## **About Lupus**

Lupus is an autoimmune disease in which the body attacks its own tissues, causing widespread inflammation and tissue damage in the affected organs. It can affect the joints, skin, brain, lungs, kidneys, and blood vessels. The **SELECT-SLE Research Study** is evaluating an investigational drug for lupus.

### About Clinical Research Studies

The main objective of a clinical research study is to learn as much as possible about the safety and efficacy of potential new drugs. These studies must be completed before a new drug can be made available to the public. Every day, research uncovers new information about medical conditions and possible therapies. Right now, there are more than 400,000 clinical studies in progress all over the world.<sup>1</sup>





# This study is being conducted by:

[lupus-selectsle.com]
Scan the code with your
camera app and tap:



Select-SLE &

AbbVie\_M23-699\_SLE\_Recruitment Brochure\_USE\_PA3\_V2.0\_14February2025

JAKa-AA-0092-RM, Version 2.0, Approved: 02/2025



A Clinical Research Study for Systemic Lupus Erythematosus (SLE)



## Lupus Doesn't Stop

#### Neither Do You

Your journey with lupus may be demanding. Let's explore an option for potential relief along the way. Join a community seeking answers for lupus through clinical research.





## **Study Qualifications**

You may be able to participate in the **SELECT-SLE Research Study** if you:



Are between 18 and 63 years old



Have been diagnosed with lupus for at least 6 months



Have been feeling lupus symptoms despite being consistently treated for lupus

If you are interested in participating, the study doctor or staff will review additional study criteria with you.

## Benefits of Participation

Taking part in a clinical research study may offer several benefits including:



Getting actively involved in your own healthcare



Having access to the investigational drug



Helping others by progressing medical research

Qualified participants will receive all study-related drugs (the active investigational drug or placebo) and study-related care at no cost. Participants may be compensated for travel and expenses.

## Study Details



During the first part of the **SELECT-SLE Research Study**, after establishing initial eligibility, study participants will have an equal chance of receiving either the investigational drug (a tablet taken by mouth) or a placebo (something that looks like the investigational drug but has no effect on the body), on top of other lupus treatments participants were already receiving.

This period involves up to 15 study clinic visits, and the duration is up to 52 weeks.

After completion of the first part of the research study, participants will then have the opportunity to join 2 long-term extension periods in which all participants will receive the active investigational drug. The first extension period involves an additional 5 study clinic visits and an additional duration of 52 weeks. The second extension period involves an additional 9 study clinic visits and an additional duration of 104 weeks.

